Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension. No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected by multiple myel...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Bruno, Giulia, Bringhen, Sara, Maffei, Ilaria, Iannaccone, Andrea, Crea, Teresa, Ravera, Agnese, Astarita, Anna, Vallelonga, Fabrizio, Salvini, Marco, Gay, Francesca, Veglio, Franco, Milan, Alberto
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://ncbi.nlm.nih.gov/pubmed/31058856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11050622
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires